Distribution of HBV, HCV and HIV results of the inpatients or outpatients, who had been treated for various diagnoses in Diyarbakır Training and Research Hospital between 2005 and 2012, among years was investigated.Files of the patients, who had been treated as inpatient or outpatient 992. to any diagnosis between 01/01/2005 and 31/12/2012 in the clinics or policlinics of Diyarbakır 581 due Training and Research Hospital, were retrospectively reviewed using patient file database. Serum samples (235.534 for HBsAg, 196.727 for Anti-HBs antibody, 98.497 for HBeAg, 97.417 for Anti-HBe antibody, 225.483 for HCV and 138.923 for HIV) of these patients, which had been processed in microbiology laboratory, were studied by chemiluminescence technique using Roche E-170 (Modular Analytics System) device.Prevalence rates between 2005 and 2012 were as follows: 15.9%-9% for HBsAg, 32.9%-52.3% for Anti-HBs, 2.5%-1.8% for HBeAg, 30.4%-25.2% for Anti-HBe, 1%-0.7% for Anti-HCV, and 0.1%-1% for Anti-HIV. Increase in Anti-HBs prevalence is the successful outcome of routine immunization in population. This suggests that, governmental policies focused on this subject have resulted in successful outcomes and that people also take care about this.A prevalence rate decreasing to 9% from 15.9% for HBsAg and prevalence rate increasing to 52.3% from 32.9% for Anti-HBs antibody positivity in 8-year period in our region is quite meaningful. Such favorable developments in our region are of great valuable in terms of indicating to what extent could struggle against HBV is controlled by education and awareness.

This study analyzed a host of parasite agents and bacterial viruses in 1,079 children aged 0 to 5 years suffering from diarrhea between 2004 and 2008. Enteric pathogens were detected in 767 (71%) infected patients and 456 control patients. Enteric pathogens were isolated from 41 (8.9%) of the infected patients. Isolated pathogens responsible for gastroenteritis were as follows: Rotavirus 282 (26.1%), Shigella 19 (1.7%), enteropathogenic Escherichia coli 153 (60.9%), entero-invasive E. coli 30 (11.9%) and enterotoxigenic E. coli 68 (27%). Among the E.

The aim of this study was to determine the pathogenic agents, which have been isolated in ICUs and determine their antimicrobial susceptibility in the first two years of our hospital. Methods: A total 368 strains (194 Pseudomonas aeruginosa, and 174 Acinetobacter baumannii) that were considered as an infectious agent and isolated from different clinical samples of hospitalized patients in intensive care units between January 2011 and December 2012 were included in the study. Conventional methods and automatized system were used for the identification and antibiotic susceptibility of the isolates with according to guidelines of Clinical and Laboratory Standarts Institute (CLSI). Imipenem and meropenem resistance has been confirmed by the E test method and interpreted according to CLSI. Results: Resistance rates of P.aeruginosa strains were as follows: Meropenem 35%, imipenem 36%, cefepim 21%, ceftazidim and ciprofloxacin 29%, gentamicin 33%, piperacilin/tazobactam 35%, amikacin 37%. Resistance rates of A.baumannii strains were as follows: Meropenem 85%, imipenem 87%, amikacin 22%, trimethoprim/sulfamethoxazole 25%, gentamicin 46%, piperacilin/tazobactam 54%, ampicilin/sulbactam 59%, cefepim 64%, ciprofloxacin 71%, ceftazidim 83%. Conclusion: Increased carbapenem resistance in our ICUs demonstrates importance of antimicrobial susceptibility tests. The antibiotic susceptibility tests should be surveyed continuously to avoid the spread of intensive care unit isolates carrying high level antibiotic resistance for better achievement of treatment regimens.

No abstract

No abstract